Aurélien Maurizot

Aurélien Maurizot

Auto-generated profile, based on publicly available information

Aurélien Maurizot

Vascular Medicine Unit, Cardiology Department, Versailles Hospital, Le Chesnay, France

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2023 in Vascular
Verified
Journal Article
Closed access
AMAurélien Maurizot
Aurélien Maurizot
SCSimon Chabay
Simon Chabay
GRGuillaume Roger
Guillaume Roger
STStéphanie Tapiero
Stéphanie Tapiero
JGJean-Louis Georges
Jean-Louis Georges
AFAlexis Ferré
Alexis Ferré
Introduction: The high prevalence of deep vein thrombosis (DVT) in patients admitted to intensive care unit (ICU) for COVID-19-related acute respiratory distress syndrome (ARDS) would justify systematic screening of these patients or higher therapeutic dose of heparin for thromboprophylaxis. Material and method: We performed a systematic echo-Doppler of the lower limb proximal veins during the first 48 h (visit 1) and from 7 to 9 days after visit 1 (visit 2) in consecutive patients admitted to the ICU of a university-affiliated tertiary hospital for severe proven COVID-19 during the second wave. All patients received intermediate-dose heparin (IDH). The primary objective was to determine DVT incidence on venous Doppler ultrasound. Secondary objectives were to determine whether the presence of DVT modifies the anticoagulation regimen, the incidence of major bleeding according to International Society on Thrombosis and Haemostasis (ISTH) criteria, and the mortality rate of patients with and without DVT. Results: We included 48 patients (30 [62.5%] men) with a median age of 63 years [IQR, 54–70]. The prevalence of proximal deep vein thrombosis was 4.2% (2/48). In these two patients, after DVT diagnosis, anticoagulation was changed from intermediate to curative dose. Two patients (4.2%) had a major bleeding complication according to ISTH criteria. Among the 48 patients, 9 (18.8%) died before hospital discharge. No DVT or pulmonary embolism was diagnosed in these deceased patients during their hospital stay. Conclusion: In critically ill patients with COVID-19, management with IDH results in a low incidence of DVT. Although our study is not designed to demonstrate any difference in outcome, our results do not suggest any signal of harm when using intermediate-dose heparin (IDH) COVID-19 with a frequency of major bleeding complications less than 5%.

23 February 2022 in JMV-Journal de Médecine Vasculaire
Verified
Journal Article
Closed access
FAFranck Assayag
Franck Assayag
JGJean-Louis Georges
Jean-Louis Georges
SCSimon Chabay
Simon Chabay
MKMehrsa Koukabi
Mehrsa Koukabi
SLS. Lancien
S. Lancien
AMAurélien Maurizot
Aurélien Maurizot

1 October 2021 in JMV-Journal de Médecine Vasculaire
Verified
Journal Article
Closed access
GRGuillaume Roger
Guillaume Roger
AMA. Maurizot
A. Maurizot
SCS. Chabay
S. Chabay
STS. Tapiero
S. Tapiero
JSJ. Soltani
J. Soltani
BLB. Livarek
B. Livarek

1 February 2017 in JMV-Journal de Médecine Vasculaire
Verified
Journal Article
Closed access
AMA. Maurizot
A. Maurizot
ABA. Bura-Rivière
A. Bura-Rivière
KGK. Gritli
K. Gritli
LBL. Bertoletti
L. Bertoletti
LHL. Hernández-Blasco
L. Hernández-Blasco
MMM. Monreal
M. Monreal